Breakthrough in Type 1 Diabetes Treatment: Sana Biotechnology Announces Positive Clinical Data on Insulin-Producing Islet Cells Transplanted Without Immunosuppression

Sana Biotechnology has published groundbreaking clinical data in the New England Journal of Medicine showing that its hypoimmune-modified, insulin-producing islet cells can persist and function over time in a patient with type 1 diabetes without immunosuppression. The study demonstrates the ability to genetically modify and transplant pancreatic islet cells without immunosuppression and overcome both allogeneic and autoimmune rejection. Sana is incorporating this technology to develop SC451, a HIP-modified, stem cell-derived therapy as a one-time treatment for patients with type 1 diabetes.